(1) Publication number:

**0 113 57**0 Δ1

(12)

## **EUROPEAN PATENT APPLICATION**

(21) Application number: 83307692.0

(2) Date of filing: 16.12.83

(5) Int. Cl.3: C 07 D 233/88

C 07 D 233/60, C 07 D 401/04 C 07 D 401/06, A 61 K 31/415

30 Priority: 20.12.82 US 450848

Date of publication of application: 18.07.84 Bulletin 84/29

Designated Contracting States:
 AT BE CH DE FR GB IT LI LU NL SE

7) Applicant: MERCK & CO. INC. 126, East Lincoln Avenue P.O. Box 2000 Rahway New Jersey 07065(US)

(7) Inventor: Chabala, John C. 560 Sherwood Parkway Westfield New Jersey 07090(US)

(7) Inventor: Fisher, Michael H. R.D. 1, Old York Road Ringoes New Jersey 08551(US)

(2) Inventor: Patchett, Arthur A. 1090 Minisink Way Westfield New Jersey 07090(US)

(2) Representative: Crampton, Keith John Allen et al, D YOUNG & CO 10 Staple Inn London WC1V 7RD(GB)

54 5-(Amino or substituted amino) imidazoles.

(5) 5-(Amino or substituted amino) imidazoles of the formula:

$$R_2 \longrightarrow R_4$$

in which  $R_1$  is (a) mono-substituted phenyl or monosubstituted phenalkyl where the substituent is trifluoromethyl,  $C_{2\cdot3}$  alkanoyl, nitro, carboxy, alkoxycarbonyl, acetamido,  $C_{1\cdot3}$  alkylthio,  $C_{1\cdot3}$  alkylsulfonyl or

570

ш

where n is from 1 to 5,  $R_5$  is as defined below and X is O, S, SO, SO<sub>2</sub>, CH<sub>2</sub>, CO, CHOH, CHCN or  $C \cong NR_6$  where  $R_6$  is hydrogen,  $C_{1.3}$  alkyl, hydroxy,  $C_{1.3}$  alkoxy, amino,  $C_{1.3}$  alkylamino, or di( $C_{1.3}$  alkylamino; (b) phenyl or phenalkyl having from two to five  $R_5$  substituents where each  $R_5$ , independently of the other(s), is halogen, cyano, tri-

fluoromethyl,  $C_{2:3}$  alkanoyl, nitro,  $C_{1:3}$  alkyl,  $C_{1:3}$  alkoxy, carboxy, alkoxycarbonyl, trifluoromethoxy, acetamido,  $C_{1:3}$  alkylsulfonyl, trichlorovinyl, trifluoromethylthio, trifluoromethylsulfinyl, trifluoromethylsulfonyl or

where  $R_{\rm B}$ , X, and n are as defined above, provided that if the monosubstituent or one of the polysubstituents is halogen,  $C_{1-3}$  alkyl or  $C_{1-3}$  alkoxy, such atoms or groups are in positions other than those *ortho* to the positions of attachment of the phenyl to the imidazole or the alkyl that is in turn attached to the imidazole; or (c) phenacyl, pyridyl, pyridylmethyl, naphthyl, naphthyl, quinolyl, or quinolylmethyl;

 $\rm R_2$  is amino, C<sub>1 3</sub> alkylamino, di(C<sub>1.3</sub> alkyl)amino, acetamido, acetimido, ureido, formamido, formimido or guanidino:

 $\mathsf{R}_3$  is carbamoyl, cyano, carbazoyl, amidino or N-hydroxycarbamoyl; and

J...

R<sub>4</sub> is hydrogen, C<sub>1.3</sub> alkyl, hydroxy, amino, C<sub>1.3</sub> alkylamino, di(C<sub>1.3</sub> alkyl)amino, phenyl, cyano. C<sub>1.3</sub> alkoxy, C<sub>2.3</sub> alkanoyloxy, C<sub>1.3</sub> alkylshio, C<sub>1.3</sub> alkylsulfonyl are novel and possess anticoccidial activity. The compounds are useful for controlling caecal and or intestinal coccidiosis when administered in minor quantities to animals, in particular to poultry, usually in admixture with animal sustenance.

`..

1

## 5-(AMINO OR SUBSTITUTED AMINO) IMIDAZOLES

This invention relates to anticoccidial compounds and their preparation.

Coccidiosis is a widespread poultry disease produced by infections of protozoa of the genus Eimeria, which causes severe pathology in the intestines and caeca of poultry. Some of the most significant of these species are E. tenella, E. acervulina, E. necatrix, E. brunetti, E. maxima, E. mitis, E. mivati, E. hagani and E. praecox. The disease is generally spread by the birds picking up the infectious organism in droppings on contaminated litter or ground or by way of food or drinking water. The disease is 10 manifested by haemorrhage, accumulation of blood in the caeca, passage of blood to the droppings, weakness and digestive disturbances. The disease often terminates in death but the market value of fowl that survive severe infections is substantially reduced as a result. Coccidiosis is therefore a disease of great economic importance and extensive work has been done to 15 find new and improved methods for controlling and treating coccidial infections in poultry.

This invention is based on the discovery that certain novel 5-amino and substituted amino imidazoles and certain of their substituted derivatives have a surprisingly and unexpectedly high degree of activity against coccidiosis of poultry.

The present invention provides a compound having the formula:

5

10

in which  $R_1$  is (a) mono-substituted phenyl or mono-substituted phenalkyl where the substituent is trifluoromethyl,  $C_{2-3}$  alkanoyl, nitro, carboxy, alkoxycarbonyl, acetamido,  $C_{1-3}$  alkylsulfinyl,  $C_{1-3}$  alkylsulfinyl or

where n is from 1 to 5,  $R_5$  is as defined below and X is O, S, SO, SO<sub>2</sub>,  $CH_2$ , CO, CHOH, CHCN or  $C=NR_6$  where  $R_6$  is hydrogen,  $C_{1-3}$  alkyl, hydroxy,  $C_{1-3}$  alkoxy, amino,  $C_{1-3}$  alkylamino, or  $di(C_{1-3}$  alkyl)amino; (b) phenyl or phenalkyl having from two to five  $R_5$  substituents where each  $R_5$ , independently of the other(s), is halogen, cyano, trifluoromethyl,  $C_{2-3}$  alkanoyl, nitro,  $C_{1-3}$  alkyl,  $C_{1-3}$  alkoxy, carboxy, alkoxycarbonyl, trifluoromethoxy, acetamido,  $C_{1-3}$  alkylthio,  $C_{1-3}$  alkylsulfinyl, trifluoromethylsulfinyl, trifluoromethylsulfinyl, trifluoromethylsulfinyl or

where R<sub>5</sub>, X, and n are as defined above, provided that if the monosubstituent or one of the polysubstituents is halogen, C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkoxy, such atoms or groups are in positions other than those <u>ortho</u> to the positions of attachment of the phenyl to the imidazole or the alkyl that is in turn attached to the imidazole; or (c) phenacyl, pyridyl, pyridylmethyl, naphthyl, naphthylmethyl, quinolyl, or quinolylmethyl;

 $R_2$  is amino,  $C_{1-3}$  alkylamino, di( $C_{1-3}$  alkyl)amino, acetamido, acetimido, ureido, formamido, formimido or guanidino;

R<sub>3</sub> is carbamoyl, cyano, carbazoyl, amidino or N-hydroxycarbamoyl; and

 $R_4$  is hydrogen,  $C_{1-3}$  alkyl, hydroxy, amino,  $C_{1-3}$  alkylamino,  $di(C_{1-3}$  alkyl)amino, phenyl, cyano,  $C_{1-3}$  alkoxy,  $C_{2-3}$  alkanoyloxy,  $C_{1-3}$  alkylthio,  $C_{1-3}$  alkylsulfinyl, or  $C_{1-3}$  alkylsulfonyl. Preferably, when a given  $R_5$  is defined so as to include a second  $R_5$  group, then that second  $R_5$  group cannot itself be defined so as to include a third  $R_5$  group.

5

10

Administration of a small amount of at least one of the compounds of the invention, preferably in a composition with an inert carrier, conveniently a poultry feed, can be effective in preventing or greatly reducing the incidence of coccidiosis. Such compositions are another aspect of the present invention. The compounds are effective against both the caecal form (caused principally by <u>E. tenella</u>) and the intestinal forms (principally caused by <u>E. acervulina</u>, <u>E. brunetti</u>, <u>E. maxima</u> and <u>E. necatrix</u>). The coccidiostats of this invention are particularly effective against the species that cause caecal damage in addition to preventing the pathology caused by the coccidia. These compounds also exert an inhibitory effect on the oocysts by greatly reducing the number and or the sporulation of those produced. They are administered in compositions that also include an inert carrier.

The compounds of the invention are also active against **Eimeria spp**, in other animals.

The novel imidazole derivatives of this invention are prepared by reacting an appropriately substituted halide and a 1-unsubstituted imidazole compound in the presence of a base in a suitable reaction medium.

5

10

15

20

The preferred compounds of the invention are those in which, in the structural formula, R is monosubstituted monosubstituted benzyl where the substituent is a trifluoromethyl, phenoxy, benzoyl, phenylthio, phenylsulfinyl or phenylsulfonyl radical or a halosubstituted, methyl-substituted or trifluoromethyl-substituted phenoxy, phenylthio, phenylsülfinyl, phenylsulfonyl, benzoyl or phenylhydroxymethyl radical; a di- or trisubstituted phenyl or benzyl radical where the substituents are halogen, cyano, methyl, trifluoromethyl, phenoxy, benzoyl, phenylthio, phenylsulfinyl, phenylsulfonyl, or a halo-substituted, methylsubstituted or triflüoromethyl-substituted phenoxy, phenylthio, phenylsulfinyl, phenylsulfönyl, benzoyl or phenylhydroxymethyl radical; provided that if the monosubstituent or one of the substituents is halogen, it is ortho to the position of attachment of the phenyl to the imidazole or to the methyl that is in turn attached to the imidazole;

 $R_2$  is amino, lower alkylamino or di(loweralkyl) amino;  $R_3$  is carbamoyl and  $R_{\it h}$  is hydrogen.

The especially preferred compounds of the invention are those in which R<sub>1</sub> is a phenyl or benzyl radical having 2 or 3 halo, cyano, methyl," trifluoromethylphenoxy, halophenoxy, tolyoxy, trifluoromethyl, halophenylthio, tolylthio, trifluoromethylphenylthio, halophenylsulfinyl, tolysulfinyl, trifluoromethylphenylsulfinyl, halophenylsulfonyl, tolylsulfonyl, methylbenzoyl, halobenzoyl, trifluoromethylphenylsulfonyl, methylphenylhalophenyl-hydroxymethyl, trifluoromethylbenzoyl, hydroxymethyl and/or trifluoromethylphenyl-hydroxymethyl substituents in the meta and/or para positions;

R<sub>2</sub> is amino;

5

10

R<sub>3</sub> is carbamoyl; and

R<sub>h</sub> is hydrogen.

In the present specification and claims the term "loweralkyl" means  ${}^{\text{"C}}_{1-3}$  alkyl", viz. methyl, ethyl, propyl or isopropyl; the term "loweralkoxy" means  ${}^{\text{"C}}_{1-3}$  alkoxy", viz. methoxy, ethoxy, propoxy, or isopropoxy; and the term "lower alkanoyl" means  ${}^{\text{C}}_{2-3}$  alkanoyl, viz. acetyl and propionyl.

The compounds of the invention may be prepared by any one of several processes. The most general process is outlined in the following reaction scheme.

## Reaction Scheme I

5

where X is a halogen preferably chlorine or bromine. In the foregoing reaction a 1-unsubstituted but otherwise appropriately substituted imidazole is

5

10

15

30

reacted with a halogen substituted R<sub>1</sub> group in the presence of a base to prepare the desired 1-substituted imidazole. The reaction is carried out in a solvent which may be any polar aprotic organic solvent such as acetone, dimethylformamide, acetonitrile, dioxane, and the like in the presence of a base. The base may be any non-nucleophilic organic or inorganic base since its purpose is merely to neutralize the acid produced during the course of the reaction. Suitable inorganic bases are alkali metal bases, such as sodium and potassium carbonates, phosphates, bicarbonates and hydroxides. Suitable organic bases are tertiary amines such as trialkyl substituted amines and cyclic aromatic amines such as collidine. The reaction rate varies greatly with the nature of the proposed substituent at the R<sub>1</sub> position, the base being used in the reaction and the solvent. Very reactive substituent and base combinations may be complete in as little as ten minutes and at the other extreme the reaction may 20 take as long as two weeks. Most reactions are however complete in from 1 to 100 hours. reaction is carried out at a temperature of from room temperature to 100°C or to the reflux temperature of the solvent system being used. The products of the 25 reaction are isolated using techniques known to those skilled in the art.

An alternate procedure for preparing the imidazole compounds wherein  $R_2$  is amino and  $R_3$  is carbamoyl is outlined in the following reaction scheme:

16859IA

#### Reaction Scheme 2

5

10

15

20

30

$$NC \xrightarrow{NH_2} CONH_2 + R_1-NH_2 \xrightarrow{(C_2H_50)_3CR_4}$$

$$H_2NOC \xrightarrow{N} R_4$$

wherein  $\mathbf{R}_{\mathbf{d}}$  is hydrogen, loweralkyl, or phenyl. The above reaction is carried out in a non-polar aprotic solvent system as described in the preceding reaction scheme. The reaction is carried out by first combining the aminocyanoacetamide and triethylorthoformate in the solvent and stirring at from room temperature to 100°C or to the reflux temperature of the solvent system being employed for from 10 minutes to 3 hours. Generally this phase of the reaction is complete in from 1/2 to 1 hour. However, following this reaction period the R<sub>1</sub> substituted amine is added to the reaction mixture and the reaction stirred for up to 2 hours at from room temperature to 25 100°C or the reflux temperature of the reaction system. The reaction is oftentimes very fast being evidenced by the immediate production of a precipitate and the product may be isolated immediately. However, generally to insure that the reaction is complete, stirring and heating are continued for a short time. The products of the reaction are isolated using techniques known to those skill d in the art.

5

10

15

20

25

30

The novel compounds of this invention are orally administered to poultry for the control and prevention of coccidiosis. Any number of conventional methods are suitable for administering the coccidiostats of this invention to poultry, as for example, they may be given in the poultry feed. The actual quantity of the coccidiostats administered to the poultry in accordance with this invention will vary over a wide range and be adjusted to individual needs, depending upon species of the coccidia involved and severity of the infection. The limiting criteria are that the minimum amount is sufficient to control coccidiosis and the maximum amount is such that the coccidiostat does not result in any undesirable effects.

A feed typically contains from about 0.0001 to about 0.2 percent, preferably from about 0.001 to about 0.1 percent, by weight of one of the coccidiostats of this invention. The optimum levels will naturally vary with the specific compound utilized and species of <a href="Eimeria">Eimeria</a> involved, and can be readily determined by one skilled in the art. Levels of the 5-amino and substituted amino imidazoles of this invention, in poultry feed of from about 0.001 percent to about 0.1 percent by weight of the diet are especially useful in controlling the pathology associated with <a href="E. tenella">E. tenella</a>, as well as the intestinal dwelling species.

Depending on the compound employed, levels of 0.001 percent to 0.006 percent possess the novel effects of reducing the number of oocysts passed in the droppings of infected chickens and/or inhibiting the subsequent division and maturation to infectivity,

scientifically designated as the process of sporulation. Thus, the combination of prevention of pathology, coupled with the inhibiting effect on the reproductive product of these organisms, the oocysts, present a unique two-fold method for the control of coccidiosis in poultry.

The quantity or concentration of a novel coccidiostat of this invention in any admixture in which it is administered to the poultry will, of course, vary in accordance with the type of admixture utilized.

Of the various methods of administering the coccidiostats of this invention to poultry, they are most conveniently administered as a component of a feed composition. The novel coccidiostats may be 15 readily dispersed by mechanically mixing the same in finely ground form with the poultry feedstuff, or with an intermediate formulation (premix) that is subsequently blended with other components to prepare 20 the final poultry feedstuff that is fed to the Typical components of poultry feedstuffs include molasses, fermentation residues, corn meal, ground and rolled oats, wheat shorts and middlings, alfalfa, clover and meat scraps, together with 25 mineral supplements such as bone meal and calcium carbonate and vitamins.

The following non-limiting examples will serve to further illustrate the instant invention.

30

5

10

## EXAMPLE 1

## Preparation of 1-substituted-5-aminoimidazole-4carboxamides (Method A)

A mixture of 5-aminoimidazole-4-carboxamide hydrochloride, potassium carbonate, alkyl halide, and

16859IA

acetone were refluxed together for from 3 to 168 hours, the solvent was concentrated to about 1/6 of the original volume and the mixture filtered. The solid was washed with acetone, slurried in water, and filtered. The remaining solid was slurried in water, treated wth glacial acetic acid to remove residual potassium carbonate, and filtered. The filter cake was washed with water, acetone, and ether to provide the desired 1-substituted-5-aminoimidazole-4-carbox-amide. (Table 1).

.

1877P/

- 13 -

16859IA

Table 1

1877P/		- 14 -	•	16859IA		
-		•		Table 1	(cont'd)	
C1	3.09	10.5	<b>ź</b> 0	26	2.5	296-281.5 <sup>2</sup>
c) 6.5	4.9	16.6	300	29	5.8	237-241
0 <sub>2</sub> H 21.15	4.9	16.6	300	3	1.2	. <del>219-22</del> 1
G 3.5	1.95	6.6	125	48	1.54	192.5-194 <sup>2</sup>

1877P/		- 15 -		16859ZA		
•				Table 1	(cont'd)	
Br 8.3	4.9	15.6	200	90	1.95	206-209
6.95	4.9	15.6	200	· <b>21</b>	2.3	<del>107</del> -215

In this case crude solid product was recrystallized from 65 ml acetic acid-water (10:3 v/v).

<sup>2</sup> Helting point after recrystallization from aqueous ethanol.

16859IA

Other compounds which can be prepared by

Method A:

\_\_\_\_\_R<sub>1</sub>\_\_\_\_\_

10

20

5

30

- 17 -

. 16859IA

## EXAMPLE 2

# Preparation of l-substituted-5-aminoimidazole-4-carboxamides (Method B)

A mixture of aminocyanoacetamide and triethyl orthoformate in acetonitrile was refluxed for 30-55 minutes. The mixture may be filtered if a small amount of precipitate forms. A primary amine, R<sub>1</sub>NH<sub>2</sub>, was added and the mixture was refluxed for 15-30 minutes. The mixture was cooled and product collected by filtration (Table 2) or isolated by chromatography.

15

20

25

30

	·		(cep) •	
	melting point (°C)	190-194	242.5-254 (dec)	262-263
		1.5	9.1	7.1
•	additional reflux time	<b>S</b>	00	30
Table 2	weight amine (g)		2.16	. 28 2
<u>Tab</u> )	eanine Ri=NH?	E STATE OF THE STA	CH <sub>3</sub>	C1
	reflux time (min.)	<b>\$</b>	000	00
	CH <sub>3</sub> CW	e	90	00
	. (BLO)3CH CH3CW	62. E	3.29	3.30
	NG CONH2 (R)	2.00	2.00	2.00

18779/

168591A

18779/		- 19 -		16859TA				
				Table 2 (cont'd)	<del>p</del> .	,		
3.46	2.48	<b>2</b>	\$	To To	2.40	\$	1.97	
2.56	£ .	\$2	\$	CH <sub>3</sub> o	80 FT. ED	92	3.55	236-238
2.00	3.29	0	\$		5.13	<b>S</b>	<b>*</b> :	188-191
0.297		\$ <b>.</b>	<b>\$</b>	CI C	0.528	2	609	238-240

1877P/		. 50.		16859TA Tebla 2 (see) 43	•			•
0.531	0.817	. 0	•	2 HM 2 ID	1.02	я̂ ч	0.885	235-237
1. 48	2.48	, 23 , 23	\$	CI CINA	2.85	 <b>:</b>	3.66	247-249
. 00 . 00	3.29	o e	05		1.92	<i>ਹ</i> ੀ ਵ	1.05	198.5-2001
0.273	0.454	<b>4</b> :1	\$	c1 ( ) -0- ( )	0.751	â	0.340	199-200

18779/		- 21 -	168591A				-
1.2A	2.05	18	\$ 7	(P.1	·.	;	;
					:	97.7	201-202
0.500	0.620	eo eo	\$ - mH3	0.785	<b>S</b> 1	0.831	258-260
			3				
0.870	1.43	<b>a</b>	\$ , mar	1.38	13	1.62	264-270
			<b>&gt;</b>				

18779/			- - - -	·	168591A <u>Isble 2</u> (cont'd)	÷		•	
0.700	•	1.252	<b>2</b> ,	\$	2 2 3	1.24	2	1.22	275
0,556	•	\$ \$0 .0	٠ •	<b>S</b>	C WHAT	1.79	2		221-222
0.914		6 6	o. •	\$	CI C	0.845 . 15	. 51	0.741	229-230

		0.592 226-227	221-223
			0.350 45 0.121 221-223
		90	\$
	(p.:	0.830	0.350
168591 <b>A</b>	Table 2 (cont'd)	G G G G G G G G G G G G G G G G G G G	Cr <sub>3</sub> C <sub>1</sub>
		\$	\$
- 23 -		<b>4</b>	1,5
		0.52	0.183
18772/			0.117

Melting point after recrystallization from 98:2 (v/v) ethanol-benzene.

Weight of triethylorthoacetate.

Yield of 1-(3,4-dichlorobenzyl)-2-methyl-5-aminoimidazole-4-carboxamide, isolated in two crops, triturated with 20 ml of hot acetonitrile and dried.

- 24 -

16859IA

Other compounds which can be prepared by

Method B:

10 <u>R</u>1 <u>R</u>1 ...

CF<sub>2</sub>—CR<sub>2</sub>— BC—CR<sub>2</sub>— Cl—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>—CR<sub>2</sub>

20

ca<sup>2</sup>—ca<sup>2</sup>— ca<sup>2</sup>—ca<sup>2</sup>—

25 CT<sub>2</sub> CT<sub>2</sub> CT<sub>2</sub> CT<sub>2</sub>

30

#### EXAMPLE 3

## Preparation of 1-(m-cyanobenzyl)-5-aminoimidazole-4carboxamide

A mixture of 5-aminoimidazole-4-carboxamide (5.00 g), potassium carbonate (12.0 g), and  $\alpha$ -bromo-5 m-tolunitrile (9.80 g) were refluxed in acetone (300 ml) for 24 hours under a nitrogen atmosphere. The mixture was cooled to room temperature and filtered. The solid residue was washed with acetone and the combined filtrates were evaporated to dryness. The 10 residual solid was dissolved in acetone (50 ml), concentrated to a volume of 20 ml in vacuo, and diluted with diethyl ether (100 ml) to provide a The solvent was decanted from the residue and deposited crystals of crude product on standing. 15 gum was triturated twice with acetone, and the acetone layers were combined with the above crystals, and evaporated to provide 5.9 g of a dark gum. gum was dissolved in methanol (100 ml), filtered, added to 100 ml. E. Merck 7734 silica gel, and 20 evaporated to dryness in vacuo. The product on silica gel was placed on top of a column of 1200 ml E. Merck 7734 silica gel and eluted with 9:1 v/v methylene chloride/methanol. After a forerun of 1.0 1, 400 ml fractions were collected and fractions 8-11 25 and 12-15 were combined separately and evaporated to The solid product from fractions 8-11 was triturated with a small volume of acetone and filtered. The filtrate was combined separately with the product from fractions 12-15 and evaporated to 30 dryness. The product was recrystallized from methanol to provide 320 mg of  $1-(\underline{m}$ -cyanobenzyl)-5aminoimidazole-4-carboxamide, m.p. 246-247°C.

## EXAMPLE 4

<u>Preparation of 1-(4-chloro-3-trifluoromethylbenzyl)-5-aminoimidazole-4-carboxamide</u>

5 A mixture of 5-aminoimidazole-4-carboxamide hydrochloride (5.0 g),  $K_2CO_3$  (16.5 g), and a 9:1 w/w mixture of  $\alpha$ , 4-chloro-3-trifluoromethyltoluene and  $\alpha$ , 2-dichloro-3-trifluoromethyltoluene were refluxed in acetone (300 ml) for 4 days. Solvent was concentrated in vacuo, the residue was diluted with 10 water, and the solution was extracted with ethyl acetate. The combined ethyl acetate extracts were washed with brine,  $0.5 \, \underline{N}$  acetic acid, and brine, dried, treated with activated charcoal, and filtered. The filtrate was concentrated to provide a 15 first crop of 3.40 g. The filtrate was diluted with ether to provide a second crop of 2.07 g, and the remaining filtrate was diluted with hexane to provide a third crop of 0.25 g. The second and third crops were combined, dissolved in aqueous ethanol, diluted 20 with water, and concentrated to provide 0.97 q of solid. Further concentration of the filtrate provided an additional 0.43 g. The samples weighing 3.40 g, 0.97 g, and 0.43 g were combined, treated with hot 7.5% methanol in ethyl acetate, and diluted 25 with 50 ml ethyl acetate. The resulting solution was chromatographed on a column of 500 ml silica gel, eluted with 7.5% methanol in ethyl acetate followed by 10% methanol in ethyl acetate. A total of 150 30 fractions of 20 ml each were collected at a flow rate of about 10 ml/min. Fractions 60-118 were combined and evaporated to provide 3.53 g solid. The product was dissolved in 100 ml of boiling ethanol, treated

16859IA

with activated charcoal, and filtered. The filtrate was concentrated to provide a first crop of crystals, and further concentration of the filtrate provided a second crop. The two crops were combined and recrystallized from 50 ml of ethanol to provide 1.99 g 1-(4-chloro-3-trifluoromethylbenzyl)-5-amino-imidazole-4-carboxamide, m.p. 230.5-232.5°C.

#### **CLAIMS**

## 1. A compound having the formula:

in which  $R_1$  is (a) mono-substituted phenyl or mono-substituted phenalkyl where the substituent is trifluoromethyl,  $C_{2-3}$  alkanoyl, nitro, carboxy, alkoxycarbonyl, acetamido,  $C_{1-3}$  alkylthio,  $C_{1-3}$  alkylsulfinyl,  $C_{1-3}$  alkylsulfinyl or

where n is from 1 to 5,  $R_5$  is as defined below and X is O, S, SO, SO<sub>2</sub>,  $CH_2$ , CO, CHOH, CHCN or  $C=NR_6$  where  $R_6$  is hydrogen,  $C_{1-3}$  alkyl, hydroxy,  $C_{1-3}$  alkoxy, amino,  $C_{1-3}$  alkylamino, or  $di(C_{1-3}$  alkyl)amino; (b) phenyl or phenalkyl having from two to five  $R_5$  substituents where each  $R_5$ , independently of the other(s), is halogen, cyano, trifluoromethyl,  $C_{2-3}$  alkanoyl, nitro,  $C_{1-3}$  alkyl,  $C_{1-3}$  alkoxy, carboxy, alkoxycarbonyl, trifluoromethoxy, acetamido,  $C_{1-3}$  alkylthio,  $C_{1-3}$  alkylsulfinyl,  $C_{1-3}$  alkylsulfonyl, trichlorovinyl, trifluoromethylthio, trifluoromethylsulfinyl, trifluoromethylsulfonyl or

where  $R_5$ , X, and n are as defined above, provided that if the monosubstituent or one of the polysubstituents is halogen,  $C_{1-3}$  alkyl or

C<sub>1-3</sub> alkoxy, such atoms or groups are in positions other than those <u>ortho</u> to the positions of attachment of the phenyl to the imidazole or the alkyl that is in turn attached to the imidazole; or (c) phenacyl, pyridyl, pyridylmethyl, naphthyl, naphthyl, quinolyl, or quinolylmethyl;

 $R_3$  is amino,  $C_{1-3}$  alkylamino, di( $C_{1-3}$  alkyl)amino, acetamido, acetimido, ureido, formamido, formimido or guanidino;

R<sub>3</sub> is carbamoyl, cyano, carbazoyl, amidino or N-hydroxycarbamoyl; and

 $R_4$  is hydrogen,  $C_{1-3}$  alkyl, hydroxy, amino,  $C_{1-3}$  alkylamino, di( $C_{1-3}$  alkyl)amino, phenyl, cyano,  $C_{1-3}$  alkoxy,  $C_{2-3}$  alkanoyloxy,  $C_{1-3}$  alkylsulfinyl, or  $C_{1-3}$  alkylsulfinyl.

A compound as claimed in Claim I, in which R is monosubstituted 2. phenyl or monosubstituted benzyl where the substituent is a trifluoromethyl, phenoxy, benzoyl, phenylthio, phenylsulfinyl or phenylsulfonyl radical or a halo-substituted, methyl-substituted or trifluoromethyl-substituted phenoxy, phenylthio, phenylsulfinyl, phenylsulfonyl, benzoyl or phenylhydroxymethyl radical; a di- or trisubstituted phenyl or benzyl radical where the substituents are halogen, cyano, methyl, trifluoromethyl, phenoxy, benzoyl, phenylthio, phenylsulfinyl, phenylsulfonyl, or a halo-substituted, methylphenylthio, trifluoromethyl-substituted phenoxy, substituted or phenylsulfinyl, phenylsulfonyl, benzoyl or phenylhydroxymethyl radical; provided that if the monosubstituent or one of the substituents is halogen, it is ortho to the position of attachment of the phenyl to the imidazole or to the methyl that is in turn attached to the imidazole;

 $R_2$  is amino,  $C_{1-3}$  alkylamino or di( $C_{1-3}$  alkyl)amino;  $R_3$  is carbamoyl and  $R_4$  is hydrogen.

3. A compound as claimed in Claim 2, in which R<sub>1</sub> is a phenyl or benzyl radical having 2 or 3 halo, cyano, methyl, trifluoromethyl, halophenoxy,

tolyoxy, trifluoromethylphenoxy, halophenylthio, tolylthio, trifluoromethylphenylthio, halophenylsulfinyl, tolysulfinyl, trifluoromethylphenylsulfinyl, halophenylsulfonyl, tolylsulfonyl, trifluoromethylphenylsulfonyl," halobenzoyl, methylbenzoyl," trifluoromethylbenzoyl, halophenyl-hydroxymethyl, methylphenylhydroxymethyl and/or trifluoromethylphenyl-hydroxymethyl substituents in the meta and/or para positions;

 $R_2$  is amino;  $R_3$  is carbamoyl; and  $R_n$  is hydrogen.

- 4. 5-Amino-1-(3,4,5-trichlorobenzyl)imidazole-4-carboxamide.
- 5. 5-Amino-1- [ 4-(4-chlorophenylthio)-3-chlorobenzyl] imidazole-4-carboxamide.
- 6. 5-Amino-1-[ 4-(4-chlorophenoxy)-3-chlorobenzyl ] imidazole-4-carboxamide.
- 7. A process for the preparation of a compound as claimed in Claim 1 comprising reacting a compound having the formula

with an  $R_1$ -substituted halide in the presence of a base to produce the desired compound,  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  being as defined in Claim 1.

8. A process for the preparation of a compound as claimed in Claim 1 and having the formula.

comprising treating aminocyanoacetamide with an  $R_1$ -substituted amine in the presence of a compound of formula  $(C_2H_5O)_3CR_6$  to produce the desired compound,  $R_6$  being hydrogen,  $C_{1-3}$  alkyl, or phenyl and  $R_1$  and  $R_4$  being as defined in Claim 1.

- 9. A compound as claimed in any one of Claims 1 to 6 for use in administration to an animal for the purpose of preventing or treating coccidiosis.
- 10. A composition useful for the prevention and treatment of coccidiosis which comprises an inert carrier and a compound as claimed in any one of Claims 1 to 6.

### **CLAIMS FOR AUSTRIA**

## 1. A process for preparing a compound of formula

$$R_2$$
 $R_2$ 
 $R_1$ 

comprising reacting a compound having the formula

with an  $R_1$ -substituted halide in the presence of a base to produce the desired compound, where in the formula,  $R_1$  is (a) mono-substituted phenyl or mono-substituted phenalkyl where the substituent is trifluoromethyl,  $C_{2-3}$  alkanoyl, nitro, carboxy, alkoxycarbonyl, acetamido,  $C_{1-3}$  alkylsulfinyl,  $C_{1-3}$  alkylsulfonyl or

where n is from 1 to 5,  $R_5$  is as defined below and X is O, S, SO, SO<sub>2</sub>,  $CH_2$ , CO, CHOH, CHCN or  $C=NR_6$  where  $R_6$  is hydrogen,  $C_{1-3}$  alkyl, hydroxy,  $C_{1-3}$  alkoxy, amino,  $C_{1-3}$  alkylamino, or  $di(C_{1-3}$  alkyl)amino; (b) phenyl or phenalkyl having from two to five  $R_5$  substituents where each  $R_5$ , independently of the other(s), is halogen, cyano, trifluoromethyl,  $C_{2-3}$  alkanoyl, nitro,  $C_{1-3}$  alkyl,  $C_{1-3}$  alkoxy, carboxy, alkoxycarbonyl, trifluoromethoxy, acetamido,  $C_{1-3}$  alkylthio,  $C_{1-3}$  alkylsulfinyl,  $C_{1-3}$  alkylsulfonyl, trichlorovinyl, trifluoromethylthio, trifluoromethylsulfinyl, trifluoromethylsulfonyl or

where  $R_5$ , X, and n are as defined above, provided that if the monosubstituent or one of the polysubstituents is halogen,  $C_{1-3}$  alkyl or  $C_{1-3}$  alkoxy, such atoms or groups are in positions other than those ortho to the positions of attachment of the phenyl to the imidazole or the alkyl that is in turn attached to the imidazole; or (c) phenacyl, pyridyl, pyridylmethyl, naphthyl, naphthylmethyl, quinolyl, or quinolylmethyl;

 $\rm R_2$  is amino,  $\rm C_{1-3}$  alkylamino, di(C $_{1-3}$  alkyl)amino, acetamido, acetimido, ureido, formamido, formimido or guanidino;

 ${
m R}_{3}$  is carbamoyl, cyano, carbazoyl, amidino or N-hydroxycarbamoyl; and

 $R_4$  is hydrogen,  $C_{1-3}$  alkyl, hydroxy, amino,  $C_{1-3}$  alkylamino, di( $C_{1-3}$  alkyl)amino, phenyl, cyano,  $C_{1-3}$  alkoxy,  $C_{2-3}$  alkanoyloxy,  $C_{1-3}$  alkylthio,  $C_{1-3}$  alkylsulfinyl, or  $C_{1-3}$  alkylsulfonyl.

A process for preparing a compound having the formula

comprising treating aminocyanoacetamide with an  $R_1$ -substituted amine in the presence of a compound of formula  $(C_2H_5O)_3CR_6$  to produce the desired compound,  $R_6$  being hydrogen,  $C_{1-3}$  alkyl, or phenyl and  $R_1$  and  $R_4$  being as defined in Claim 1.

3. A process as claimed in Claim 1 as applied to the preparation of a compound in which  $R_1$  is monosubstituted phenyl or monosubstituted benzyl where the substituent is a trifluoromethyl, phenoxy, benzoyl, phenylthio, phenylsulfinyl or phenylsulfonyl radical, a halo-substituted, methyl-

substituted trifluoromethyl-substituted or phenoxy. phenylthio. phenylsulfinyl, phenylsulfonyl, benzoyl or phenylhydroxymethyl radical; a dior trisubstituted phenyl or benzyl radical where the substituents are halogen, cyano, methyl, trifluoromethyl, phenoxy, benzoyl, phenylthio, phenylsulfinyl, phenylsulfonyl, or a halo-substituted, methyl-substituted or trifluoromethyl-substituted phenoxy, phenylthio, phenylsülfinyl," phenylsulfonyl, benzoyl or phenylhydroxymethyl radical; provided that if the monosubstituent or one of the substituents is halogen, it is ortho to the position of attachment of the phenyl to the imidazole or to the methyl that is in turn attached to the imidazole;

 $R_2$  is amino,  $C_{1-3}$  alkylamino or di( $C_{1-3}$  alkyl)amino;  $R_3$  is carbamoyl and  $R_\mu$  is hydrogen.

- 4. A process as claimed in Claim 2 as applied to the preparation of a compound in which  $R_1$  is as defined in Claim 3 and  $R_4$  is hydrogen.
- 5. A process as claimed in Claim 1 or 2 as applied to the preparation of a compound in which R<sub>1</sub> is phenyl or benzyl radical having 2 or 3 halo, cyano, methyl, trifluoromethyl, halophenoxy, tolyoxy, trifluoromethylphenoxy, halophenylthio. tolylthio, trifluoromethylphenylthio, halophenylsulfinyl, tolysulfinyl, trifluoromethylphenylsulfinyl, halophenylsulfönyl." tolylsulfonyl," trifluoromethylphenylsulfonyl, halobenzoyl." methylbenzoyl, trifluoromethylbenzoyl," halophenyl-hydroxymethyl," methylphenyl-" hydroxymethyl and/or trifluoromethylphenyl-hydroxymethyl substituents in the  $\underline{\text{meta}}$  and/or  $\underline{\text{para}}$  positions; and  $R_u$  is hydrogen.
- 6. A process as claimed in Claim 1 or 2 as applied to the preparation of 5-amino-1-(3,4,5-trichlorobenzyl)imidazole-4-carboxamide.
- 7. A process as claimed in Claim 1 or 2 as applied to the prepration of 5-amino-1- [4-(4-chlorophenylthio)-3-chlorobenzyl] imidazole-4-carboxamide.

- 8. A process as claimed in Claim 1 or 2 as applied to the preparation of 5-amino-1-[4-(4-chlorophenoxy)-3-chlorobenzyl]imidazole-4-carboxamide.
- 9. A compound obtained by a process as claimed in any one of Claims 1 to 8 for use in administration to an animal for the purpose of preventing or treating coccidiosis.
- 10. A composition useful for the prevention and treatment of coccidiosis which comprises an inert carrier and a compound obtained by a process as claimed in any one of Claims 1 to 8.



## EUROPEAN SEARCH REPORT

	DOCUMENTS COM			T	EP 83307692.0
Category	Citation of document of n	with indication, where a elevant passages	appropriata,	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CI. 3)
A .	<u>US - A - 4 26</u> * Claim 1		(USSEN)	1,2	C 07 D 233/88
A	EP - A1 - 0 0 YAKUHIN K.K.K	.)	KEDA	1,2	C 07 D 401/04 C 07 D 401/06 A 61 K 31/41
A	CHEMICAL ABST 9, March 1, 19 USA SUMITOMO CHEMI	 RACTS, vol. 982, Columb	us, Ohio,	1,2	
	methylimidazol page 613, colu 68 990k & Jpn. Kokai	les" umn 2, abst	ract-no.	·	
	JP 81 79 671				TECHNICAL FIELDS SEARCHED (Int. CI. <sup>3</sup> )
A	CHEMICAL ABSTF 17, April 26, Ohio, USA	RACTS, vol. 1982, Colur	96, no. mbus,	1,2	C 07 D 233/00 C 07 D 401/00
	TH. KAUFFMANN cyclopolyaroma page 757, colu 142 826e	tics XII"			
	& Chem. Ber. 1	982 115(2), 	, · 452 <b>–</b> 8		
L	The present search report has t	been drawn up for all cid	sims		
	Place of search VIENNA		on of the search	T	Examiner
	· · · · · · · · · · · · · · · · · · ·	20-03-	1984		BRUS
X : partic Y : partic docum	CATEGORY OF CITED DOCU ularly relevant if taken alone ularly relevant if combined we nent of the same category ological background rritten disclosure		T: theory or pris E: earlier paters after the fillin D: document cit L: document cit	g care lad in the enci	ing the invention ut published on, or lication Basons
0:non-w P:interm	ritten disclosure rediate document		& : member of th	A Tame nates	t family, corresponding



## **EUROPEAN SEARCH REPORT**

EP 83307692.0

	•		
	D CUMENTS CONSIDERED TO BE RELEVANT		CLASSIFICATION OF THE APPLICATION (Int. CL.)
Category	C-tation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	CHEMICAL ABSTRACTS, vol. 94, no. 13, March 30, 1981, Columbus,	1,2	
	Ohio, USA  PFIZER CORP. "Imidazole derivatives"  page 747, column 1, abstract-no.  103 363r  & Neth. Appl. 79 06 148		
A	CHEMICAL ABSTRACTS, vol. 97, no. 25, December 20, 1982, Columbus, Ohio, USA	1,2	TECHNICAL FIELDS SEARCHED (Int. Cl. <sup>3</sup> )
	SANKYO KAGAKU K.K. "8-Quinoline- sulfonyl derivatives" page 855, column 2, abstract-no. 216 195t		
	& Jpn. Kokai Tokkyo Koho JP 82 116 067 		
	•		
	•		